TIP389: Buffett's Core Principles w/ Dev Kantesaria

Episode Summary

Executive Summary: Dev Contessaria explains how his path from Harvard Medical School and biotech venture capital led him to a concentrated public-equity strategy built on Buffett/Munger principles: buy dominant compounding businesses at attractive prices, hold patiently, and avoid speculative or capital-intensive sectors. He emphasizes reading-intensive research, margin of safety, disciplined valuation, and selective flexibility during extreme events like COVID.

Main Topics: Career pivots and investing edge (Priority: 5/5): Contessaria describes leaving medicine after realizing clinical practice wasn't his long-term path, then moving through McKinsey and 18 years in venture capital before public equities. He argues venture experience sharpened his ability to assess future risk and business quality. Buffett/Munger-style compounding machine investing (Priority: 5/5): He says the core of his philosophy is buying high-quality businesses with durable pricing power, operating leverage, and the ability to compound intrinsic value for long periods, rather than chasing cheap cyclical 'cigar butt' stocks. Research process, patience, and opportunity timing (Priority: 4/5): Valley Forge does not rely on stock screens; it reads filings continuously and prepares to act quickly when mispricings appear. The firm targets only a few new ideas per year and wants to be ready when a temporary dislocation creates an attractive entry point. Portfolio concentration and hedge fund structure (Priority: 4/5): He explains how the firm’s stable capital base and investor alignment allow a concentrated portfolio similar in spirit to Buffett’s long-term patience, despite operating in a hedge fund structure rather than an insurance-float model. COVID recession playbook and selective flexibility (Priority: 5/5): In 2020 the portfolio saw no new names or sales, but the firm did add a large short position early in the pandemic based on a temporary informational advantage from medical contacts. He views this as a rare but justified deviation from standard process. Sector exclusions and circle of competence (Priority: 4/5): Valley Forge avoids biotech, pharma, medical devices, hardware, minerals, and commodity- or rate-sensitive businesses because their returns depend on hard-to-predict R&D, commodity prices, or capital intensity. It prefers essential, dominant businesses with durable economics. Valuation, cash use, and sell discipline (Priority: 4/5): He frames valuation through discounted cash flow and free-cash-flow yield versus the 10-year Treasury, but stresses the real edge is estimating future risk factors. Selling is driven by deteriorating quality, leverage, capital-allocation mistakes, or better opportunities elsewhere.

Key Arguments: The best long-term way to build wealth is to buy exceptional businesses that can compound intrinsic value, not to hunt for statistically cheap stocks that may be value traps. Venture capital experience improves public-equity investing because it trains one to synthesize many future risk factors into a single risk/reward judgment. Stock screens are insufficient for finding durable compounders; the work must come from deep reading of filings and continual reassessment of intrinsic value. A concentrated portfolio can be advantageous if the manager has high conviction, stable capital, and the ability to act quickly when mispricings are short-lived. There is almost no bad time to buy a true compounding machine, especially in a low-rate environment; the key is buying at a fair price and holding for years. Macro forecasting is not the core edge; the firm instead focuses on business quality, free cash flow growth, and a large gap between business yield and risk-free rates. During exceptional situations, such as the early COVID period, temporary informational advantages can justify a rare short position or other deviation from normal rules. Capital allocation quality is a major factor in holding or selling; buybacks, compensation, and acquisitions are evaluated as real economic costs.

Data Points: Assets under management: $2.7 billion - Valley Forge Capital Managed current size Firm history: 14 years - Length of Valley Forge's public-equity track record Venture capital experience: 18 years - Dev Contessaria's time in biotech ventures before public equities McKinsey tenure: 2 years - Transition step after leaving medical school Investor base: 100 capital accounts across roughly 90 investors - Structure cited during discussion of COVID volatility COVID-era investor calls: Only 1 call - Investor reaction during March 2020 market panic 2020 performance: Over 27% - Fund return during COVID year, helped partly by a short position Short positions taken: About 5 times in 14 years - Rarity of shorting in the fund Performance contribution from short: 6% of 2020 performance - Attribution from the March 2020 short position Cash allocation historical high: 20% - Past portfolio cash level Current cash allocation: Low single digits - More recent portfolio cash level Idea frequency: 1 to 3 great ideas a year - Target number of new high-conviction investments Portfolio composition: 8 to 12 picks - Approximate concentration level referenced by the discussion Most recent market rates cited: 10-year Treasury at 1.4% to 1.5% - Used as proxy for risk-free rate SP 500 earnings yield cited: Roughly 5% - Compared against the 10-year Treasury Expected portfolio growth: High teens overall, some low 20s - Management's expectation for free cash flow per share growth Typical entry discount: 30% to 60% below intrinsic value - Desired margin of safety when buying Winner/loser record since inception: 39 winners and 6 losers - Fund's long-term batting average over 14 years Worst loss impact: About 4% drag - Largest single loser in 2010 Moody's / S&P Global upside: About 20x to 25x from low points - How much these holdings appreciated over 12 years Large losers that were near break-even: 3 of 6 - Most losing positions were modestly negative or flat

Pivotal Quotes: "it is like you are reading the Bible. It is a universal truth." — Dev Contessaria: On discovering Warren Buffett and Charlie Munger's investing philosophy "there is really, even for me today, there's only one universal truth, only one path that makes sense to me. And that is to buy really high-quality businesses" — Dev Contessaria: On his core investing framework centered on compounding businesses "there really is almost no bad time to buy a compounding machine." — Dev Contessaria: On timing purchases of durable high-quality companies

Implications: Listeners should focus less on macro prediction and more on owning durable businesses with pricing power, low capital intensity, and disciplined capital allocation. The episode reinforces that patience, concentration, and a narrow circle of competence can outperform when combined with rigorous valuation and fast action on dislocations.